Aerobid license agreement
Forest Labs announced it has entered into an agreement with Key for the rights to Aerobid, and anti-asthmatic metered-dose inhaler product. Key licensed the $2.4 mil.-per-year product from patent holder Syntex, which markets the drug in spray form under the brandname Nasalide.
You may also be interested in...
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
A detailed report published by Medicines for Europe setting out policies affecting the off-patent industry across 22 European countries demonstrates the urgent need for pricing and reimbursement and procurement reforms, the association insists.
The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.